SAP SE

  • WKN: 716460
  • ISIN: DE0007164600
  • Land: Deutschland

Nachricht vom 12.12.2011 | 15:27

SAP AG: Release according to Article 30e of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


SAP AG  / Third country release according to Article 30e Para. 1, No. 3
of the WpHG [the German Securities Trading Act]

12.12.2011 15:27

Dissemination of a Post-admission Duties announcement according to Article
30e Para. 1 No. 3 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------


With ad hoc announcement dated December 3, 2011 SAP AG ('SAP') announced
that SAP's subsidiary, SAP America, Inc., has entered into a definitive
merger agreement with SuccessFactors, Inc. ('SuccessFactors') pursuant to
which a subsidiary of SAP would offer to acquire all outstanding shares of
common stock of SuccessFactors. In connection with this merger agreement,
SAP has filed on December 9, 2011 with the U.S. Securities and Exchange
Commission (SEC) the following documents:

A Schedule TO-C including 
- 'Exhibit (a)(5)(O) - Transcript of Barclays Capital Global Technology
Conference held on December 8, 2011'

These documents are available on the website of SAP AG under 
http://www.sap.com/corporate-en/investors/successfactors/offer.epx.



12.12.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      SAP AG
              Dietmar-Hopp-Allee 16
              69190 Walldorf
              Germany
Internet:     www.sap.com
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------

GBC-Fokusbox

CytoTools vor Einführung von DermaPro

Die Markteinführung des Hauptproduktes DermaPro steht bei der CytoTools AG kurz bevor. Wir rechnen bereits 2014 mit den ersten Produktionserlösen und 2015 mit den ersten Vermarktungserlösen. Zusätzliche Marktpotenziale werden dabei durch die Ausweitung auf weitere Indikationsgebiete erschlossen. Bei einem fairen Wert je Aktie von 73,30 € lautet unser Rating KAUFEN.

News im Fokus

adidas AG: adidas AG aktualisiert Ausblick angesichts der jüngsten Entwicklungen in Russland/GUS sowie der anhaltenden Schwäche des Golfmarkts und gibt strategische Maßnahmen bekannt, um Wachstum sicherzustellen und voranzutreiben

31. Juli 2014, 08:45

Aktueller Webcast

Fresenius Medical Care AG & Co. KGaA

Q2 2014 Conference Call

31. Juli 2014

Aktuelle Research-Studie

Evotec AG

Original-Research: Evotec AG (von Montega AG): Halten

31. Juli 2014